Gerald L. Andriole Jr., MD
Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, St. Louis, MissouriGerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri.
Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.
Dr. Andriole has over 30 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 300 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, the Prostate Cancer Early Detection Panel of the National Comprehensive Cancer Network, American Surgical Association and the American Association of Genitourinary Surgeons among other societies.
Recent Contributions to PracticeUpdate:
- Negative Multiparametric Prostate MRI Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
- The Controversy Over PSA Testing Stumbles On
- Reevaluating PSA Testing Rates in the PLCO Trial
- Targeted Biopsies Miss Clinically Significant Prostate Cancer Lesions
- Prostate Cancer Location May Help Stratify Patient Risk
- Postoperative Statins and Risk for Recurrence Following Radical Prostatectomy
- Transperineal Sector Biopsy Is Another Option in Detecting Prostate Cancer
- 5α-Reductase Inhibitors Not Associated With Risk for High-Grade/Lethal Prostate Cancer